Group 1 - The seller, LFG Investment Holdings (03938), has agreed to sell 299 million shares, representing approximately 61.43% of the total issued shares, to the offeror, Fortune Origin International Capital (Holdings) Limited, for a total cash consideration of HKD 179.7 million, equating to HKD 0.60 per share [1] - The offeror will pay HKD 120 million in cash and the remaining HKD 59.6953 million through the issuance of promissory notes [1] - Following the completion of the transaction, the offeror will hold rights to a total of 299 million shares, which is about 61.43% of the total issued shares [1] Group 2 - The offeror is engaged in investment holding and is wholly owned by Mr. Chen Shaoyang, who is also the sole director of the offeror [2] - After the offer period, the offeror intends to continue the existing main business of the group without making any significant changes to operations or selling any assets, except for routine business activities [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from January 12, 2026, at 9:00 AM Hong Kong time [3]

Group 1 - The core transaction involves the acquisition of shares from A&B, Li Huaguo, and Yongjiayuan by CN BASE and the offeror, with total consideration amounting to 2,731.63 million HKD [1][2] - The agreement with A&B involves the purchase of shares equivalent to approximately 18.60% of the company's issued share capital for 14.32 million HKD, at a price of 0.50 HKD per share [1] - The agreement with Li Huaguo involves the purchase of shares equivalent to approximately 9.09% of the company's issued share capital for 7 million HKD, also at a price of 0.50 HKD per share [1] - The agreement with Yongjiayuan involves the purchase of shares equivalent to approximately 7.78% of the company's issued share capital for 5.9938 million HKD, at the same price of 0.50 HKD per share [2] Group 2 - Following the completion of these transactions, the offeror and its concert parties will collectively hold approximately 35.48% of the company's issued share capital, with the offeror holding 28.64 million shares and CN BASE holding 25.98 million shares [2] - The offeror is required to make a mandatory conditional cash offer for all issued shares at a price of 0.50 HKD per share, which represents a discount of approximately 65.75% compared to the last closing price of 1.460 HKD per share [2] - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on November 27, 2025 [2]

Core Viewpoint - The announcement details a conditional sale agreement between Anselme Limited (the offeror) and Li Jingyang (the seller) for the acquisition of 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share, which is a discount of about 68.10% compared to the market price on the announcement date [1][2]. Group 1 - The offeror will acquire 138.7 million shares, representing approximately 27.71% of the total issued share capital of Huakang Biomedical [1]. - Prior to the completion of the transaction, the offeror directly and beneficially owns 121 million shares, which is about 24.13% of the total issued share capital [1]. - Following the completion of the transaction, the offeror, Dr. Zhou, and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1]. Group 2 - The offeror is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the offeror [2]. - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2].